Canaccord Genuity Maintains a 'Buy' on Teva Pharma (TEVA); Vision Becoming More Clear After Meeting W/ CEO
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $36.81 -1.76%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target of $52.00.
Analyst, Randall Stanicky, said, "We hosted new TEVA CEO Dr. Jeremy Levin for meetings and lunch, which included a detailed discussion of his view of the platform. While the business review is ongoing we think early meetings are going well in establishing credibility with the Street. There are several questions still to be answered, but we’re starting to get a better sense as to where focus is highest. With institutional interest high and the stock under-owned we see an attractive set-up forming. The hurdle remains the binary risk from Copaxone that’s keeping many on the sidelines. A trial decision is imminent, and we think it can unlock pent-up demand with follow-through from a host of catalysts we now expect before year-end based on our meeting."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.10 yesterday.
Analyst, Randall Stanicky, said, "We hosted new TEVA CEO Dr. Jeremy Levin for meetings and lunch, which included a detailed discussion of his view of the platform. While the business review is ongoing we think early meetings are going well in establishing credibility with the Street. There are several questions still to be answered, but we’re starting to get a better sense as to where focus is highest. With institutional interest high and the stock under-owned we see an attractive set-up forming. The hurdle remains the binary risk from Copaxone that’s keeping many on the sidelines. A trial decision is imminent, and we think it can unlock pent-up demand with follow-through from a host of catalysts we now expect before year-end based on our meeting."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aurinia settles patent dispute with Teva over generic voclosporin
- NetEase.com (NTES) PT Lowered to $143 at Macquarie
- Walmart (WMT) PT Lowered to $126 at BofA Securities
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
